Metabolomic and inflammatory signatures in congenital hypothyroidism: a longitudinal analysis of levothyroxine response
By
Marcela Vela-Amieva
Isabel Ibarra-González
Raúl Calzada León
María de la Luz Ruiz-Reyes
María Eugenia Constantini
Sara Guillén-López
Lizbeth López-Mejía
Michelle Citlalli Luna-Nequiz
Rosa Itzel Carrillo-Nieto
Cynthia Fernández-Lainez
July 1, 2026
Clinical Scorecard: Metabolomic and Inflammatory Profiles in Congenital Hypothyroidism: A Longitudinal Study of Levothyroxine Treatment Response
At a Glance
Category Detail
Condition Congenital Hypothyroidism Key Mechanisms Metabolomic changes in sphingolipid metabolism and inflammatory markers (TNF-α, IL-10) Target Population Pediatric patients with confirmed congenital hypothyroidism Care Setting National Institute of Pediatrics
Key Highlights
Nine metabolites discriminated between pre-treatment and post-treatment samples. Significant changes in sphingolipid metabolism observed after levothyroxine therapy. Circulating TNF-α and IL-10 levels remained elevated post-treatment. Nutritional assessment showed modest improvement in length-for-age Z-score. Metabolomic profiling may provide insights into treatment response. Guideline-Based Recommendations
Diagnosis
Confirm congenital hypothyroidism with abnormal thyroid profile and imaging studies. Management
Initiate levothyroxine therapy at a standardized dose of 10-15 µg/kg/day. Monitoring & Follow-up
Monitor serum TSH and free T4 concentrations to achieve biochemical euthyroidism. Risks
Untreated congenital hypothyroidism can lead to irreversible neurological impairment. Patient & Prescribing Data
Newly diagnosed, untreated pediatric patients with congenital hypothyroidism.
Levothyroxine therapy leads to metabolic changes that may not be captured by traditional markers.
Clinical Best Practices
Utilize metabolomic profiling to assess treatment response in congenital hypothyroidism. Consider inflammatory markers in the monitoring of treatment efficacy. Related Resources & Content
